Labopharm Initiates Phase III Trial of Twice-Daily Pain Formulation
Posted on: Monday, 10 March 2008, 09:01 CDT
Labopharm has started enrolling patients in the Phase III clinical trial for its twice-daily, tramadol-acetaminophen combination product for treatment of acute low back pain.
The trial (study 06CCL3-001) is a multi-centre, randomized, double-blind, parallel-arm study that will compare the efficacy and safety of company's twice-daily tramadol-acetaminophen combination product. The study, which is being conducted at more than 20 centers in the US and Canada, has a treatment period of approximately one week and is expected to include more than 250 patients.
James Howard-Tripp, president and CEO of Labopharm, said: "Our formulation has the potential to be the first twice-daily tramadol-acetaminophen product, as well as to compete in the broader acute pain prescription drug market globally. Accordingly, it would be an excellent complement to our once-daily tramadol product for the treatment of persistent pain."
Source: Datamonitor
Related Articles
- JayHawk Energy Reports 58% Increase in Daily Production at Cherokee Basin
- NanoViricides and CDC Collaborate in Rabies Treatment Study
- Remoxy Meets Primary Endpoint in Pivotal Phase III Study; Pain Therapeutics Expected to File NDA Q2 2008
- Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-Treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
- Canadian Health Authority Approves THELIN (Sitaxsentan Sodium) for Pulmonary Arterial Hypertension; First Selective Endothelin A Receptor Antagonist, First Once-Daily Oral Treatment
- TorreyPines Therapeutics Completes Phase I Trial for NGX426, a Novel Oral Treatment for Pain
- YM BioSciences Pain Treatment Study Disappoints
- ValueOptions and Colorado Health Networks Win Administrative Services Only Contract; Social Security Administration's Mental Health Treatment Study Contract Awarded to Westat With ValueOptions and Colorado Health Networks Serving As ASO
- Drugs equivalent in angina treatment: study
- Palliative Treatment of Painful Disseminated Bone Metastases With ^Sup 186^Rhenium-HEDP in Patients With Lung Cancer
 |
 |
User Comments (0)
RSS Feeds